San Francisco Business Times – 2:51 PM PST Thursday
Cytokinetics Inc. said Thursday that a clinical trial of ispinesib, an experimental lung cancer treatment, failed.
The South San Francisco drug company (NASDAQ: CYTK) said the Phase II trial, run by GlaxoSmithKline, failed to meet the criteria to advance to the next stage of clinical testing.
The drug had been given to patients with platinum-sensitive non-small cell lung cancer.
Cytokinetics focuses on drugs that work on the cytoskeleton, a structure of protein filaments that give shape to cells.
Published March 30, 2006 by San Francisco Business Times